I am an adult with an eGFR of 52 mL/min/1.73 m²; what CKD stage is this and how should I manage it, including monitoring, medication adjustments, blood pressure and glycemic control, and when to refer to a nephrologist?

Management of eGFR 52 mL/min/1.73 m² (CKD Stage 3a)

An eGFR of 52 mL/min/1.73 m² indicates Stage 3a chronic kidney disease, requiring annual monitoring of kidney function and albuminuria, blood pressure control to <130/80 mmHg, optimization of glycemic control if diabetic, medication dose adjustments, and consideration of nephrology referral if albuminuria is present or eGFR continues to decline. 1

CKD Stage Classification

• Your eGFR of 52 mL/min/1.73 m² places you in Stage 3a CKD (eGFR 45-59 mL/min/1.73 m²), representing mild-to-moderate reduction in kidney function. 1
• Stage 3a alone is sufficient to diagnose CKD even without albuminuria or other markers of kidney damage. 1

Monitoring Frequency

• Assess eGFR and albuminuria at least annually for Stage 3a CKD. 1
• Measure urine albumin-to-creatinine ratio (UACR) in a random spot urine collection to quantify albuminuria. 1
• Two of three UACR specimens collected within 3-6 months should be abnormal (≥30 mg/g) before confirming persistent albuminuria, due to high biological variability. 1

Blood Pressure Management

• Target blood pressure <130/80 mmHg for all patients with CKD. 1
• If UACR is ≥30 mg/g, initiate an ACE inhibitor or ARB (but not both) to slow CKD progression and reduce cardiovascular risk. 1
• Continue ACE inhibitor or ARB unless serum creatinine rises by more than 30% within 4 weeks of initiation or dose increase. 1
• Continue ACE inhibitor or ARB even if eGFR falls below 30 mL/min/1.73 m², unless symptomatic hypotension or uncontrolled hyperkalemia develops. 1

Glycemic Control (If Diabetic)

• If you have type 2 diabetes with eGFR ≥20 mL/min/1.73 m² and UACR ≥200 mg/g, start an SGLT2 inhibitor to reduce CKD progression and cardiovascular events. 1
• If you have type 2 diabetes with eGFR ≥20 mL/min/1.73 m² and UACR 30-200 mg/g, consider an SGLT2 inhibitor to reduce CKD progression and cardiovascular events. 1
• If you have type 2 diabetes with persistent albuminuria despite maximum tolerated ACE inhibitor or ARB, consider adding a nonsteroidal mineralocorticoid receptor antagonist (eGFR >25 mL/min/1.73 m² required). 1
• If glycemic targets are not met despite metformin and SGLT2 inhibitor, add a long-acting GLP-1 receptor agonist with documented cardiovascular benefits. 1

Medication Adjustments

• Review all medications for necessary dose adjustments at eGFR 52 mL/min/1.73 m². 1
• Monitor serum creatinine and potassium when using ACE inhibitors, ARBs, or diuretics. 1
• Avoid NSAIDs, which can accelerate CKD progression and cause acute kidney injury. 1

Dietary Protein Restriction

• Target dietary protein intake of 0.8 g/kg body weight per day for non-dialysis-dependent Stage 3 CKD. 1

Cardiovascular Risk Reduction

• If you have type 2 diabetes, consider statin therapy for cardiovascular risk reduction, as CKD markedly increases cardiovascular risk. 1
• For adults ≥50 years with eGFR ≥60 mL/min/1.73 m² (or Stage 3a with eGFR 45-59), statin treatment is recommended. 1

Nephrology Referral Criteria

Refer to a nephrologist if any of the following occur: 1

• Continuously increasing UACR levels despite treatment
• Continuously decreasing eGFR despite optimization of blood pressure and glycemic control
• eGFR falls below 30 mL/min/1.73 m² (Stage 4 CKD)
• Uncertainty about the etiology of kidney disease (e.g., active urinary sediment with red/white blood cells, rapidly increasing albuminuria, rapidly decreasing eGFR, absence of diabetic retinopathy in type 1 diabetes)
• Difficult management issues including anemia, secondary hyperparathyroidism, resistant hypertension, or electrolyte disturbances

Common Pitfalls to Avoid

• Do not assume eGFR >60 mL/min/1.73 m² excludes kidney disease—normal values overlap with early CKD stages, and albuminuria must be assessed. 2
• Do not discontinue ACE inhibitor or ARB for mild creatinine increases (<30% within 4 weeks)—this is expected and does not indicate harm. 1
• Do not use both ACE inhibitor and ARB together—combination therapy increases risk of hyperkalemia and acute kidney injury without additional benefit. 1
• Hyperkalemia associated with ACE inhibitor or ARB can often be managed by reducing serum potassium rather than stopping the medication. 1